These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 26670754

  • 1. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U, Kurtoglu E, Eyigor H, Yilmaz MD, Aygener N.
    Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
    [Abstract] [Full Text] [Related]

  • 2. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Dec; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 3. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.
    Acta Haematol; 2010 Dec; 123(3):148-52. PubMed ID: 20185899
    [Abstract] [Full Text] [Related]

  • 4. New Advances in Evaluation of Hearing in a Sample of Egyptian Children with β-Thalassemia Major.
    Alzaree FA, Shehata MA, Atti MA, Elzaree GA, El-Kassas GM.
    Open Access Maced J Med Sci; 2019 May 15; 7(9):1494-1498. PubMed ID: 31198461
    [Abstract] [Full Text] [Related]

  • 5. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun 15; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

  • 6. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A.
    Haematologica; 2011 Jan 15; 96(1):41-7. PubMed ID: 20884710
    [Abstract] [Full Text] [Related]

  • 7. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V, Kurtoglu E.
    Hematology; 2013 Jan 15; 18(1):50-5. PubMed ID: 23321010
    [Abstract] [Full Text] [Related]

  • 8. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Diamantidis MD, Neokleous N, Agapidou A, Vetsiou E, Manafas A, Fotiou P, Vlachaki E.
    Int J Hematol; 2016 May 15; 103(5):537-44. PubMed ID: 26861970
    [Abstract] [Full Text] [Related]

  • 9. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 15; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 15; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 11. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun 15; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 12. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Jun 15; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 13. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity.
    Delehaye E, Capobianco S, Bertetto IB, Meloni F.
    Auris Nasus Larynx; 2008 Jun 15; 35(2):198-202. PubMed ID: 17869044
    [Abstract] [Full Text] [Related]

  • 14. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Jun 15; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 15. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up.
    Aldè M, Ambrosetti U, Giuditta M, Cassinerio E, Piatti G.
    Auris Nasus Larynx; 2024 Apr 15; 51(2):271-275. PubMed ID: 37903661
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: The era of deferasirox film coated tablet.
    Galhom DH, Talaat RM, Hanna D, Gad NH.
    Int J Pediatr Otorhinolaryngol; 2024 Feb 15; 177():111868. PubMed ID: 38252990
    [Abstract] [Full Text] [Related]

  • 19. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, Athanassiou-Metaxa M.
    Acta Otorhinolaryngol Belg; 2004 Feb 15; 58(2):113-7. PubMed ID: 15515654
    [Abstract] [Full Text] [Related]

  • 20. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
    Chao YH, Wu KH, Lin CY, Tsai MH, Peng CT, Wu HP, Lin CD.
    Pediatr Blood Cancer; 2013 Dec 15; 60(12):1963-6. PubMed ID: 23956204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.